Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Developments review uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://bookmarklayer.com/story20845546/5-simple-statements-about-conolidin-to-replace-traditional-painkillers-explained